During July, anti-infectives, pain-relief and gastroenterology medicines showed a strong double-digit growth of 14%, 11% and 15% respectively, the latest data culled from IQVIA said. The market posted a MAT (moving annual total) growth of 8% in July.
Typically, with rains across several parts of the country during June-July, there is a high incidence of viral infections, fever and vector-borne ailments, resulting in a huge sales uptick. Anti-infectives include antibiotics, antifungals and antivirals, mostly prescribed for battling bacterial and viral infections. Overall, the pharma retail market valued at around Rs 2,22,906 crore grew in single digit – 7% – in June. Augmentin, a legacy brand of GSK Pharma, gained four ranks to reach the first slot. In July 2023, it was ranked no. 2 with sales of Rs 70 crore.
The company said in the latest results for the quarter ended June 30, 2024 that its key brands – Calpol, Augmentin and T-Bact, delivered a strong growth of 10%, and gained market share. Despite it being under price control, Augmentin, a combination of amoxicillin and clavulanic acid, outpaced its respective category and gained market share, according to the company.
Among the top 10 brands, Liv-52 showed the highest growth, followed by Udiliv and Pan-D.
During July, acute therapy that includes pain and anti-infectives, showed a growth of 11%, while chronic medication, mainly anti-diabetics and cardio-vascular, grew 12%. Among the companies, Sun Pharma maintained its top position with a market share of 8% during July, the data said. Indian companies registered a growth of 11.4%, while MNCs grew 10.2% for the month.
Analysts expect the domestic market to grow at a faster pace of 10%, driven by seasonality-led good demand for acute therapies, mainly anti-infectives and respiratory products. The average market growth is around 8-9%.
